Multiple Dose Safety and Efficacy Study Evaluating CNS 7056 Versus Midazolam in Patients Undergoing Colonoscopy
- Conditions
- Sedation
- Interventions
- Registration Number
- NCT01145222
- Lead Sponsor
- Paion UK Ltd.
- Brief Summary
The purpose of this dose-response study is to assess the safety and efficacy of CNS 7056 compared with midazolam to maintain suitable sedation levels in patients undergoing colonoscopy.
- Detailed Description
This is a double-blind, randomized, parallel group, dose-response study to assess the safety and efficacy of three dose levels of CNS 7056 compared with midazolam to maintain suitable sedation levels in patients undergoing colonoscopy.
Safety assessment will include physical examinations, vital signs, ECGs, pulse oximetry measurements, capnography, clinical chemistry and hematology laboratory tests, routine drug and ethanol screening, urinalysis, pregnancy test, pain on injection using a verbal scale, and monitoring of adverse events.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 162
- Male and female patients, aged 18 to 70 years inclusive, scheduled to undergo a standard colonoscopy.
- American Society of Anesthesiologists Physical Status (ASA PS) Score I, II, or III.
- Weight range 55 to 130 kg inclusive.
- Body mass index (BMI) range 18 to 33 kg/m2 inclusive
- Patients of child-bearing potential and their partners must have been willing to use adequate contraception such as an intrauterine device, diaphragm or condom during the study and until 1 month after the last study drug administration. Childbearing potential was defined as "all patients unless they were a female post menopausal for at least 2 years, or were surgically sterile."
- Patient voluntarily signed and dated an ICF that was approved by an IRB prior to the conduct of any study procedure.
- Patient was willing and able to comply with study requirements and return for a Follow up Visit (Day 4 ± 3 day) after the colonoscopy.
- Expected duration of colonoscopy > 30 minutes.
- Patients with a suspected or diagnosed pathology of the lower GI tract that would have added to the risk of colonoscopy, such as strictures, active inflammatory bowel disease.
- ASA III patients with history of sleep apnea.
- ASA III patients with obesity (BMI ≥ 30 kg/m2).
- Patients with evidence of uncontrolled renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction, or other clinically significant (CS) findings at screening that, in the investigator's or medical monitor's opinion, should have excluded them from the study.
- Patients with clinically significant abnormalities in 12 lead ECG recorded at screening.
- Female patients with a positive serum human chorionic gonadotropin (HCG) pregnancy test at screening or baseline.
- Lactating female patients.
- Patients with positive drugs of abuse screen at baseline.
- Patients with positive serum ethanol at baseline.
- Patient with a history of drug or ethanol abuse.
- Patients in receipt of any investigational drug within 30 days or less than 7 half lives (whichever was longer) before the start of the study, or scheduled to receive one during the study period.
- Patients with a known sensitivity to benzodiazepines, flumazenil, opioids, naloxone, or a medical condition such that these agents were contraindicated.
- Patients with an inability to communicate well with the investigator.
- Patients in whom management of airway was judged to be difficult due to, e.g., thyro-mental distance ≤ 4 cm ("short neck"), or Mallampati score of 4.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description C. Remimazolam (CNS 7056) C. CNS 7056 Initial 5 mg iv for sedation induction, and 3 mg iv top-ups for sedation maintenance. Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses. B. Remimazolam (CNS 7056) B. CNS 7056 Initial 7 mg iv for sedation induction, and 2 mg iv top-ups for sedation maintenance. Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses. A. Remimazolam (CNS 7056) A. CNS 7056 Initial 8 mg iv for sedation induction, and 3 mg iv top-ups for sedation maintenance. Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses. D. Midazolam D. Midazolam Initial 2.5 mg iv for sedation induction, and 1 mg iv top-ups for sedation maintenance. Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses
- Primary Outcome Measures
Name Time Method Success Rates of the Procedure From start of study drug injection to patient discharge Success of the procedure is a composite endpoint consisting of: Modified Observer's Assessment for Alertness/Sedation (MOAA/S) scores ≤4 on three consecutive measurements after administration of study drug AND completion of the endoscopy procedure AND no requirement for rescue sedative medication AND no requirement for manual or mechanical ventilation
- Secondary Outcome Measures
Name Time Method Time to Fully Alert From last injection of double-blind study medication until fully alert criteria are reached Time to first of 3 consecutive MOAA/S scores of 5 after the last injection of double-blind study medication
Time to Ready for Discharge After the Last Injection of Double-Blind Study Medication AND after end of colonoscopy until first of 3 consecutive Aldrete scores ≥ 9 Time of the first of 3 consecutive Aldrete scores ≥ 9
Trial Locations
- Locations (9)
Wake Research Associates
🇺🇸Raleigh, North Carolina, United States
ACRI Phase I LLC
🇺🇸Anaheim, California, United States
Charlottesville Medical Research
🇺🇸Charlottesville, Virginia, United States
Options Health Research
🇺🇸Tulsa, Oklahoma, United States
Helen Keller Hospital
🇺🇸Sheffield, Alabama, United States
HOPE Research Institute
🇺🇸Phoenix, Arizona, United States
Advanced Clinical Research Associates
🇺🇸Anaheim, California, United States
Miami Research Associates
🇺🇸South Miami, Florida, United States
Stony Brook University Medical Center
🇺🇸Stony Brook, New York, United States